Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6090
Title: Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults
Authors: Konkle, Barbara A.
Oldenburg, Johannes
Pasi, John
Kulkarni, Roshni
Nolan, Beatrice
Mahlangu, Johnny
Young, Guy
Brown, Simon A.
Pabinger, Ingrid
Shapiro, Amy
Négrier, Claude
Blanchette, Victor
Ragni, Margaret V.
Dumont, Jennifer
Lethagen, Stefan
Issue Date: 2023
Source: Research and practice in thrombosis and haemostasis, 2023 (7) 6 p.102180
Pages: 102180
Journal Title: Research and practice in thrombosis and haemostasis
Abstract: Background: Recurrent joint bleeds are a major cause of morbidity in severe hemophilia. Prophylaxis with efmoroctocog alfa (a recombinant factor VIII Fc fusion protein, [rFVIIIFc]) has demonstrated benefits beyond bleed control, including joint health maintenance.; Objectives: To assess long-term efficacy and safety of rFVIIIFc prophylaxis in severe hemophilia A in phase 3 pivotal (A-LONG/Kids A-LONG) and extension (ASPIRE) studies.; Methods: Longitudinal analysis included pooled data from A-LONG/Kids A-LONG and ASPIRE. Subgroup analyses investigated outcomes in modified Hemophilia Joint Health Score or Hemophilia Joint Health Score and target joints in subjects with 4 to 5 years follow-up on individualized prophylaxis (IP), and those with the highest annualized bleeding rate (ABR) quartile during Year 1 of IP.; Results: Overall, rFVIIIFc consumption remained stable and low ABRs were maintained, with a median treatment duration of 4.2/3.4 years in subjects from A-LONG/Kids A-LONG, respectively. Median overall ABR also remained low (1.0-2.0) in subjects on IP for 4 to 5 years. Sustained improvements in modified Hemophilia Joint Health Score or Hemophilia Joint Health Score were demonstrated over a median follow-up of 3.7 years. In subjects from A-LONG/Kids A-LONG, 99.6% ( n  = 234)/100% ( n  = 9) of evaluable baseline target joints were resolved, with no recurrence in 95%/100% of target joints. In IP subjects within the highest ABR quartile in Year 1, continued improvements were observed over a median follow-up of 4.3 years in ABR and joint health, without increased factor consumption. No inhibitors or treatment-related serious adverse events were reported.; Conclusion: Previously treated subjects of all ages receiving long-term prophylaxis with rFVIIIFc had sustained clinical benefits, including improved joint health and low ABR. (© 2023 The Author(s).)
DOI: 10.1016/j.rpth.2023.102180
Resources: https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,athens&db=mdc&AN=37753224&site=ehost-live
Appears in Sites:Children's Health Queensland Publications

Show full item record

Page view(s)

8
checked on Nov 22, 2024

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.